



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/565,118	06/19/2006	Janet Bryan	F7720(V)	6151

201 7590 01/31/2008  
UNILEVER INTELLECTUAL PROPERTY GROUP  
700 SYLVAN AVENUE,  
BLDG C2 SOUTH  
ENGLEWOOD CLIFFS, NJ 07632-3100

EXAMINER
----------

FRAZIER, BARBARA S

ART UNIT	PAPER NUMBER
----------	--------------

4173

MAIL DATE	DELIVERY MODE
-----------	---------------

01/31/2008

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

## Office Action Summary

**Application No.**

10/565,118

**Applicant(s)**

BRYAN ET AL.

**Examiner**

BARBARA FRAZIER

**Art Unit**

4173

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 18 January 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 2-11 and 13-15 is/are pending in the application.
- 4a) Of the above claim(s) 11 and 13 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 2-10, 14 and 15 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some \* c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_

### DETAILED ACTION

1. Applicant's cancellation of claims 1 and 12 and amendments to claims 2-11 and 13-15 are acknowledged. It is noted that all claims are now method claims.

#### *Election/Restrictions*

2. Applicant's election without traverse of method claims in the reply filed on 1/18/08 is acknowledged.

3. Applicant's election of the species further comprising polyunsaturated fatty acids of claim 7 in the reply filed on 1/18/08 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

4. Claims 11 and 13 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 1/18/08.

#### *Claim Rejections - 35 USC § 103*

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 4173

6. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

7. Claims 2-8, 10, 14, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Smith, WO 03/003981.

The claimed invention is drawn to a method for aiding the cognitive development or cognitive performance of humans having an age of up to 18 years, the method comprising the step of administering to said human by means of an edible composition: 1) a bioavailable iron compound, and a bioavailable zinc compound in a weight ratio of from 2:1 to 5:1, and 2) at least one B vitamin (see claim 14). Applicants have further elected the method wherein the composition further comprises at least one polyunsaturated fatty acid (claim 7).

Smith teaches compositions for improving mental performance comprising B-complex vitamins, minerals, and docosahexaenoic acid (DHA) (a polyunsaturated fatty acid) and wherein the minerals comprise zinc and iron (pages 10-12). Smith teaches that the minerals are in the form of Krebs cycle intermediates, which are "highly absorbable" (page 11, lines 24-26). The amount of zinc present is about 5 mg to about 30 mg (page 12, lines 11-12) and iron may comprise about 1 mg to about 18 mg (page 12, line 14).

Smith differs from the claimed invention because it does not explicitly teach Applicant's limitation of having iron and zinc compounds in a weight ration of from 2:1 to 5:1 (claim 14) or

Art Unit: 4173

2:1 to 4:1 (claim 6), and it does not explicitly teach the composition is used to aid the cognitive development or cognitive performance of humans having an age of up to 18 years (i.e., children).

However, the weight ranges taught by Smith include iron:zinc weight ratios of 2:1 (e.g., when iron is 10-18 mg and when zinc is 5-9 mg) to 3.6:1 (e.g., when iron is 18 mg and zinc is 5 mg). Furthermore, Smith teaches that "iron deficiency, which exists in a significant number of children with learning disabilities, may be a causative factor for much of the symptomatology associated with such poor cognitive function", and that supplementation with zinc and iron "among other minerals may provide cognitive protective effects, as well as improve memory, communication, and understanding" (page 10, lines 23-28).

It would have been obvious at the time the invention was made to use the composition of Smith having an iron:zinc weight ratio of 2:1 to 3.6:1 for aiding the cognitive development or cognitive performance of humans having an age of up to 18 years, with a reasonable expectation of success.

One skilled in the art of developing compositions for aiding cognitive development or performance of humans would have been motivated to choose the specified amounts and weight ratios of iron and zinc within the amount ranges taught by Smith as a matter of routine optimization, in order to achieve the expected results of improved mental performance as taught by Smith. Furthermore, one skilled in the art would have been motivated to use the composition of Smith for aiding the cognitive development or cognitive performance of humans having an age of up to 18 years because Smith teaches that it is already known that iron deficiencies in children may be the cause of poor cognitive function, and supplementation with iron and zinc may provide cognitive protective effects against such deficiencies (page 10, lines 23-28).

Art Unit: 4173

With respect to claim 2, Smith teaches that iron may be present in an amount of about 1 mg to about 18 mg (page 12, line 14). This is encompassed by Applicant's amount of 0.1 to 30 mg.

With respect to claim 3, Smith teaches that typical iron compounds that may be present in the composition are ferrous fumarate, ferrous gluconate, ferrous sulfate, and iron polysaccharide; this is encompassed by Applicant's listing of iron compounds, which includes ferrous carboxylate salts, ferrous inorganic compounds, and iron-sugar-carboxylate compounds.

With respect to claim 4, Smith teaches that the amount of zinc present is about 5 mg to about 30 mg (page 12, lines 11-12). This is comparable to Applicant's amount of 0.5 to 20 mg, and it would have been obvious to determine workable and/or optimal amounts of zinc present as a matter of routine experimentation.

With respect to claim 5, Smith teaches that zinc may be present in the composition bound to picolinate, citrate, acetate, gluconate, glycine, monomethionine, chelates and/or ascorbate form. This is encompassed by Applicant's listing of inorganic zinc salts, zinc carboxylate salts and chelated zinc compounds.

With respect to claim 7, Smith teaches that the polyunsaturated fatty acid DHA is present in the composition (pages 15-16).

With respect to claim 8, Smith teaches that DHA is present from about 20 mg to about 200 mg in the composition; this is encompassed by Applicant's amount of up to 2 g per serving.

With respect to claim 10, Smith teaches that the B vitamins B6 and B12 are present in the composition (pages 7 and 8).

Art Unit: 4173

With respect to claim 15, Smith teaches that the composition may be in liquid form, suitably with flavored emulsions with edible oils (page 24, lines 24-27). This is encompassed by Applicant's definition of a "food composition" which comprises at least one fat (page 15, lines 17-19 of Applicant's specification).

***Response to Applicant's Remarks***

In Applicant's remarks filed 1/18/08, Applicants first argue that WO '981 does not appear to mention improving cognitive function in children, and that the development of children and their brain is very specific and is accompanied by unique problems and challenges. This statement is not found to be persuasive because Applicants have not provided any objective evidence showing that the development of children and their brain is "unique", or that the composition of Smith (which is not limited to a specific group of humans) would not work in improving the mental performance of children. Furthermore, Smith teaches that "iron deficiency, which exists in a significant number of children with learning disabilities, may be a causative factor for much of the symptomatology associated with such poor cognitive function", and the supplementation with zinc and iron "among other minerals may provide cognitive protective effects, as well as improve memory, communication, and understanding" (page 10, lines 23-28).

Applicants also argue that fortifying a foodstuff with iron and zinc is not straightforward because of the restraints of food legislation, competition between zinc and iron for uptake in the bloodstream, and a minimum level of zinc required with iron. This is not found to be persuasive because acceptable weight ranges for zinc and iron are already taught by Smith (page 12, lines

Art Unit: 4173

11-16), and Smith specifically teaches that problems with competition for absorption are overcome by using non-competitive sources of minerals called Krebs Cycle intermediates (see page 11, lines 20-27 and examples of mineral forms on page 12).

Applicants finally argue that the two facts of iron concentration in blood going up and cognitive performance being enhanced, are surprising and are an indication of non-obviousness. This is not found to be persuasive because the results are, in fact, not surprising, since Smith already teaches that the disclosed compositions improve mental performance. Additionally, Applicants have not compared the iron:zinc weight ratio of the claimed invention with the closest prior art; therefore, the Examiner cannot conclude if the iron:zinc weight ratio of the claimed invention produces unexpected results are not.

It is the Examiner's position that the results presented in the accompanying article are, in fact, expected, because the data presented only shows that the composition produces the expected result of improving mental performance as taught by Smith, and Applicants have not presented any objective evidence comparing the claimed invention with the closest prior art to show that the composition of the claimed invention produces results that are unexpected.

8. Claim 9 is rejected under 35 U.S.C. 103(a) as being unpatentable over Smith, WO 03/003981 as applied to claims 2-8, 10, 14, and 15 above, and further in view of O'Connor et al., US Patent 6,596,302.

The claimed invention and the invention of Smith are recited above. The claimed invention of claim 9 further comprises the polyunsaturated fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in a weight ratio of at least 2:1.



Art Unit: 4173

Smith further teaches that the DHA is present as DHA concentrate fish oils (page 16, line 20 and Table on page 22).

Smith differs from the claimed invention because it does not teach what other fatty acids are present in the fish oil or in what amounts.

O'Connor et al. teach that infant formulas that contain long chain polyunsaturated fatty acids (LCPs) provide enhanced neurological development of infants (col. 1, lines 10-14), and that DHA and EPA are important LCPs in the present invention (col. 8, lines 31-33). O'Connor et al. also teach that fish oils are good sources for these fatty acids, and that such fish oils are available in "high EPA" and "low EPA" varieties, the latter having a high DHA:EPA ratio, preferably at least 3:1 (col. 9, lines 13-16). O'Connor et al. further teach that supplementation of nutrient enriched formula with LCPs should preferably include DHA, and preferably should not include high levels of EPA. Low EPA fish oils are preferred for this reason if a fish oil source of DHA is employed (col. 11, lines 28-32).

It would have been obvious at the time the invention was made to use the composition of Smith with low EPA fish oil as the source of DHA as taught in O'Connor et al. to aid the cognitive development or cognitive performance of humans having an age of up to 18 years, with a reasonable expectation of success.

One skilled in the art would have been motivated to use the low EPA fish oil having the DHA:EPA ratio of at least 3:1 as taught in O'Connor et al. as the fish oil source of DHA in the composition of Smith, since the composition of Smith is directed to improving mental performance, and low EPA fish oil is the preferred source of DHA in infant formulas that provide enhanced neurological development as taught by O'Connor et al.

*Information Disclosure Statement*

9. The supplemental information disclosure statement letter filed 1/17/08 fails to comply with 37 CFR 1.98(a)(1), which requires the following: (1) a list of all patents, publications, applications, or other information submitted for consideration by the Office; (2) U.S. patents and U.S. patent application publications listed in a section separately from citations of other documents; (3) the application number of the application in which the information disclosure statement is being submitted on each page of the list; (4) a column that provides a blank space next to each document to be considered, for the examiner's initials; and (5) a heading that clearly indicates that the list is an information disclosure statement. The information disclosure statement has been placed in the application file, but the information referred to therein has not been considered.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Barbara Frazier whose telephone number is (571)270-3496. The examiner can normally be reached on Monday-Thursday 8am-4pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached on (571)272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 4173

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

BSF



SHARMILA GOLLAMUDI LANDAU  
PRIMARY EXAMINER